Vexim goes public, but falls short of €17.5m target
This article was originally published in Clinica
Executive Summary
French kyphoplasty firm Vexim has raised €11m ($14.5m) in an initial public offering on the NYSE Alternext stock exchange in Paris. The total falls short of the €17.45m that the company said it was hoping to raise last month (www.clinica.co.uk, 16 April 2012), but nonetheless could be another indication that the medtech IPO market is picking up after a sluggish few years. Vexim issued 1.15 million new shares priced at €9.50 each; market capitalisation stood at €31.6m on the day of listing. The company's lead product is its SpineJack spinal implant, which is used during kyphoplasty procedures. It has been available outside the US since March 2010, but is not yet FDA approved. Earlier this year, Vexim appointed a new CEO, Vincent Gardés, as it aims to ramp up international sales of SpineJack (www.clinica.co.uk, 4 January 2012).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.